華創陽安(600155.SH)股東劉江擬減持不超2%股份
格隆匯3月18日丨華創陽安(600155.SH)公佈,公司股東劉江在本次減持計劃實施前持有公司無限售流通股7434.94萬股股份,佔公司總股本的4.27%。上述股份系2016年公司向特定對象非公開發行取得的股份。
劉江擬自本減持計劃公告之日起15個交易日後的6個月內(2020/4/10~2020/10/9)通過集中競價交易方式減持持有的公司股份不超過3479.11萬股,即不超過總股本的2%;且在任意連續90日內,劉江通過集中競價交易方式減持股份總數不超過公司總股本的1%,即不超過1739.56萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.